Palisade Bio, Inc. (PALI)
NASDAQ:PALI
Want to see PALI full AI Analyst Report?
Top Page
Palisade Bio
(NASDAQ:PALI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-37.50% Downside)
Action:Reiterated
Date:06/12/26
The score is held down primarily by very weak financial performance (minimal revenue, large losses, and continued cash burn) and bearish technical signals (below major moving averages with negative MACD). Corporate events provide some support via a development partnership and incremental funding, but potential dilution and the lack of meaningful profitability/valuation anchors limit the overall rating.
Positive Factors
Low leverage / strong capitalization
Near-zero debt and a sizable equity base provide financial flexibility to fund clinical programs and absorb R&D volatility. This durable capital structure reduces refinancing risk and supports multi-quarter trial timelines without immediate revenue dependence.
Negative Factors
Minimal revenue and widening losses
Persistent lack of revenue and expanding operating losses reflect a pre-revenue clinical-stage model that will remain cash-negative until commercialization or partnering. This structural loss profile requires ongoing financing and limits internal reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong capitalization
Near-zero debt and a sizable equity base provide financial flexibility to fund clinical programs and absorb R&D volatility. This durable capital structure reduces refinancing risk and supports multi-quarter trial timelines without immediate revenue dependence.
Read all positive factors
Palisade Bio (PALI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$324.59M
Dividend YieldN/A
Average Volume (3M)2.76M
Price to Earnings (P/E)―
Beta (1Y)>-0.01
Revenue GrowthN/A
EPS Growth88.03%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.06
Shares Outstanding173,579,670
10 Day Avg. Volume2,733,782
30 Day Avg. Volume2,755,181
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$10.14Price Target Upside322.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Palisade Bio Business Overview & Revenue Model
Company Description
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The c...
How the Company Makes Money
null...
Palisade Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 250.00K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 250.00K | 0.00 | 0.00 |
| EBITDA | -25.43M | -16.77M | -14.42M | -12.28M | -14.24M | -24.22M |
| Net Income | -24.15M | -16.78M | -14.44M | -12.30M | -14.26M | -26.62M |
Balance Sheet | ||||||
| Total Assets | 133.31M | 134.34M | 10.88M | 14.05M | 15.76M | 12.51M |
| Cash, Cash Equivalents and Short-Term Investments | 132.63M | 133.38M | 9.82M | 12.43M | 12.38M | 10.49M |
| Total Debt | 0.00 | 71.00K | 169.00K | 369.00K | 404.00K | 199.00K |
| Total Liabilities | 5.95M | 4.96M | 3.39M | 2.74M | 3.28M | 5.15M |
| Stockholders Equity | 127.36M | 129.38M | 7.49M | 11.31M | 12.48M | 7.37M |
Cash Flow | ||||||
| Free Cash Flow | -12.40M | -10.85M | -12.19M | -11.14M | -13.37M | -14.77M |
| Operating Cash Flow | -12.40M | -10.85M | -12.19M | -11.13M | -13.36M | -14.77M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -4.00K | -10.00K | -54.00K |
| Financing Cash Flow | 137.83M | 134.44M | 9.58M | 11.19M | 15.26M | 24.61M |
Palisade Bio Technical Analysis
Positive
2.40
Price Trends
1.97
Negative
1.88
Negative
1.78
Positive
Market Momentum
-0.05
Negative
49.06
Neutral
59.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PALI, the sentiment is Positive. The current price of 2.4 is above the 20-day moving average (MA) of 1.86, above the 50-day MA of 1.97, and above the 200-day MA of 1.78, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 49.06 is Neutral, neither overbought nor oversold. The STOCH value of 59.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PALI.
Palisade Bio Risk Analysis
Palisade Bio disclosed 52 risk factors in its most recent earnings report. Palisade Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palisade Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $153.04M | -1.30 | -70.89% | ― | ― | -37.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $302.58M | -5.64 | -96.80% | ― | ― | -1.48% | |
47 Neutral | $128.61M | -1.58 | -135.60% | ― | ― | 17.43% | |
44 Neutral | $324.59M | -16.23 | -36.79% | ― | ― | 88.03% | |
41 Neutral | $238.92M | -2.80 | -137.99% | ― | 1033.89% | 36.35% |
* Healthcare Sector Average
PALI
Palisade Bio
1.84
1.14
162.86%
CRBP
Corbus Pharmaceuticals
8.31
0.42
5.32%
ELDN
Eledon Pharmaceuticals
3.81
1.21
46.54%
OBIO
Orchestra BioMed Holdings
4.08
0.98
31.61%
PYXS
Pyxis Oncology
2.13
0.92
76.03%
Palisade Bio Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Palisade Bio Shareholders Approve Charter Amendments, Governance Matters
Positive
Jun 11, 2026
At its annual meeting on June 10, 2026, Palisade Bio stockholders approved all seven proposals on the ballot, including the election of four directors to serve until the 2027 meeting and ratification of Baker Tilly US, LLP as independent auditor f...
Business Operations and StrategyPrivate Placements and Financing
Palisade Bio partners with Iterative Health to advance PALI-2108
Positive
Apr 2, 2026
On March 30, 2026, Palisade Bio, Inc. entered into a master services agreement with Iterative Scopes, Inc., doing business as Iterative Health, to support and accelerate patient enrollment for an anticipated Phase 2 study of its ulcerative colitis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.